INSP stock forecast, quote, news & analysis
Inspire Medical Systems Inc operates as a medical technology company... Show more
Why Inspire Medical Systems (INSP) Is Up +2% in the Last 30 Days
Key Takeaways
- INSP stock rose approximately +2% over the past 30 days, recovering from April lows amid anticipation for Q1 earnings, though post-earnings reaction pressured shares.
- Over the past quarter, shares declined -24%, driven by reimbursement uncertainties, coding changes for Inspire V, and lowered full-year guidance.
- Q1 2026 earnings beat estimates with revenue up 1.6% YoY to $204.6 million and adjusted EPS of $0.10, but weak 2026 guidance citing headwinds led to sharp sell-off.
- Reimbursement disruptions from CPT code transition (64582) and Inspire V launch challenges were primary drivers of volatility and downward pressure.
- Analyst price target cuts post-earnings reflect caution, with consensus around $55-$70, maintaining mostly Hold/Neutral ratings.
Inspire Medical Systems (INSP) Company Overview and Market Position
Inspire Medical Systems, Inc. (INSP) develops and commercializes the Inspire therapy, an innovative implantable neurostimulation system for treating moderate to severe obstructive sleep apnea (OSA) in patients unable to use or adhere to CPAP (continuous positive airway pressure) machines. The company's core business model revolves around its FDA-approved PMA (premarket approval) device, which stimulates the hypoglossal nerve to keep the airway open during sleep, offering a mask-free alternative with high patient compliance.
Operating in the medical devices sector focused on sleep apnea treatments, Inspire holds a pioneering position as the first and only FDA-approved neurostimulation therapy for OSA. Competitors include traditional CPAP providers like ResMed (RMD) and emerging therapies, but Inspire's minimally invasive approach and strong clinical data provide a competitive edge. Recent stock behavior ties directly to its exposure to reimbursement policies and product launches, with coding changes impacting procedure economics and hospital adoption.
Inspire Medical Systems (INSP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INSP stock advanced +2%, closing at $54.84 on May 4, 2026, from around $53.64 on April 1, 2026. The movement was volatile and range-bound, with shares dipping to $52.03 mid-April before rebounding to highs near $58 in late April ahead of earnings, reflecting steady but cautious trading.
For the past quarter, the stock fell -24%, from $72.10 on February 3, 2026, to $54.84. The decline was trend-driven downward, punctuated by brief spikes like a 15% jump on February 26 amid CMS coding hopes, but weighed by consistent pressure from guidance cuts and analyst downgrades. Trading volume spiked on key news days, underscoring event-driven volatility.
What Drove INSP Stock Price in the Last 30 Days
The modest 30-day uptick stemmed from pre-earnings optimism, as investors anticipated a potential beat amid prior quarters' track record. Shares climbed from April lows around $52, buoyed by market sentiment in healthcare devices and hopes for positive updates on Inspire V reimbursement.
However, Q1 2026 results on May 4 triggered a sharp reversal: revenue of $204.6 million (+1.6% YoY) topped estimates, and adjusted EPS hit $0.10 versus expected -$0.28, but full-year 2026 guidance was slashed to $825-$875 million (-4% to -10% YoY) and adjusted EPS to $0.75-$1.25, citing coding disruptions (CPT 64582 transition) and WISeR program implementation. This led to a post-earnings drop of over 16% to around $45.78 intraday May 5, erasing monthly gains.
Sector influences included broader medtech caution, but company-specific reimbursement woes dominated, with analysts like Baird, Mizuho, and Wells Fargo cutting targets post-earnings while holding Neutral/Outperform ratings.
What Drove INSP Stock Performance Over the Last Quarter
The quarterly -24% slide reflected sustained reimbursement headwinds following Inspire V launch challenges. February saw sharp volatility: post-Q4 2025 earnings beat (revenue +12% YoY), shares initially rose but plunged on lowered 2026 outlook ($950M-$1B initially) due to coding uncertainty, with multiple analyst downgrades (e.g., Wolfe to Peer Perform, price targets slashed 30-60%).
March brought a brief CMS clarification rally (C-codes for Inspire V, +11%), but persistent procedure economics issues and competitive pressures from GLP-1 drugs (e.g., Eli Lilly's Zepbound for OSA) eroded gains. Macro factors like healthcare spending caution and elevated interest rates amplified downside, with institutional selling evident in volume surges. Cumulative impact: slowed growth narrative overshadowed strong prior-year fundamentals (85%+ gross margins).
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from hundreds available, each analyzing thousands of tickers across various strategies like trend-following, mean reversion, and momentum plays. These curated bots are selected based on recent performance metrics including win rate, profit factor, and Sharpe ratio, tailored to different timeframes from intraday to long-term swings. Users can review detailed backtests, live results, and risk profiles to select bots aligning with their portfolio needs. While past performance does not guarantee future results, this section highlights innovative tools for automated trading. Explore Trending AI Robots today to enhance your stock analysis and trading efficiency.
INSP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q2 earnings for updates on reimbursement stabilization under new CPT code 64582 and Inspire V adoption rates. Progress on WISeR program implementation and hospital/ASC uptake will signal if headwinds persist into 2027 growth recovery.
Industry trends like GLP-1 competition (e.g., Zepbound OSA data) and sleep apnea market expansion remain key. Macro factors including Medicare policies, interest rates affecting medtech valuations, and overall healthcare demand could sway sentiment.
Strategic developments such as international expansion, new FDA indications, or partnerships will be catalysts. Risks include prolonged coding disruptions or regulatory shifts; watch analyst revisions and volume for institutional flows.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
INSP in +5.24% Uptrend, growing for three consecutive days on July 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INSP advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 24, 2026. You may want to consider a long position or call options on INSP as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
INSP moved above its 50-day moving average on July 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The Aroon Indicator entered an Uptrend today. In of 215 cases where INSP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INSP broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.504) is normal, around the industry mean (10.755). P/E Ratio (9.398) is within average values for comparable stocks, (61.580). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.711). INSP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (1.326) is also within normal values, averaging (23.791).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices